245 related articles for article (PubMed ID: 22736425)
1. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
2. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Woo HY; Heo J; Yoon KT; Kim GH; Kang DH; Song GA; Cho M
Scand J Gastroenterol; 2012 Jul; 47(7):809-19. PubMed ID: 22563643
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
11. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Azad NS; Aragon-Ching JB; Dahut WL; Gutierrez M; Figg WD; Jain L; Steinberg SM; Turner ML; Kohn EC; Kong HH
Clin Cancer Res; 2009 Feb; 15(4):1411-6. PubMed ID: 19228742
[TBL] [Abstract][Full Text] [Related]
12. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in advanced hepatocellular carcinoma.
Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
Schmid I; Häberle B; Albert MH; Corbacioglu S; Fröhlich B; Graf N; Kammer B; Kontny U; Leuschner I; Scheel-Walter HG; Scheurlen W; Werner S; Wiesel T; von Schweinitz D
Pediatr Blood Cancer; 2012 Apr; 58(4):539-44. PubMed ID: 21922643
[TBL] [Abstract][Full Text] [Related]
17. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
18. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
19. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
